Elevance Health reported strong Q2 2026 results, with adjusted earnings per share of $7.45 surpassing analyst estimates of $6.21 and revenue of $49.83 billion beating forecasts. CEO Gail Boudreaux showed confidence by purchasing 680 shares at $366.41 each, increasing her stake. The company raised its full-year adjusted earnings guidance to at least $27.00 per share and operating cash flow forecast to $6.00 billion, driven by lower medical costs and solid operations. This positive outlook lifted shares 1.8% in pre-market trading, reflecting investor optimism about Elevance's growth and financial health.
DBV Technologies has filed a prospectus with the U.S. SEC to renew its At-The-Market (ATM) offering program, allowing it to raise up to $150 million by selling American Depositary Shares (ADSs). The funds will primarily support expanding manufacturin...
Glencore has amended and restated its $5 million convertible loan agreement with Tantalex Lithium Resources Corporation, splitting the loan into three facilities with adjusted terms and interest rates. The amended agreement includes a 1% gross revenu...
A Race Against Blindness, an Arizona nonprofit, has launched its first electric vehicle fundraiser featuring a 2025 Volkswagen ID. Buzz and $20,000 cash as the grand prize. Running from July 13 to 26, the campaign aims to raise funds for clinical tri...
HSBC has upgraded Meta Platforms to a Buy rating, reflecting confidence in its new cloud computing strategy. Meta is negotiating a potential $10 billion deal to lease its computing infrastructure to AI research lab Anthropic, addressing the global ha...
CIBC lowered Clearway Energy's price target from $43 to $42, reflecting recent stock weakness but still suggesting a 25.43% upside from the current price of $33.49. The stock was added to the Zacks Rank #5 (Strong Sell) List due to a 112.20% downward...
